FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1526072406> ?p ?o ?g. }

• W1526072406 endingPage "83" @default.
• W1526072406 startingPage "1375" @default.
• W1526072406 abstract "It has been proposed that diverse anticancer drugs and radiation therapy may induce a mode of cell death with the characteristics of apoptosis. Since apoptosis is under the control of several oncogenes, we analyzed the expression of the protein encoded by the proto-oncogenes bcl-2 and p53. Furthermore, we studied cell proliferation [using PC-10 mAb to proliferating cell nuclear antigen (PCNA)] and vascularization [using the CD-31 mAb and by counting intratumoral microvessel density (IMD)] using immunocytochemistry. A series of 73 patients with clinical stage II-IV squamous cell invasive carcinoma of the head and neck (H&N) were treated with concurrent chemoradiation therapy (cisplatin, 80 mg/m2, versus carboplatin, 375 mg/m2, three times every 3 weeks and a total dose of radiation therapy of 64 Gy in 6-8 weeks). We correlated the expression of these markers, determined prior to treatment, with response to the therapy and prognosis. Bcl-2 protein was expressed in 37.4% of the carcinomas (25/67 evaluable), and it was not significantly associated with any other feature studied. Forty (56. 4%) of the 71 carcinomas evaluable for p53 were p53 positive; the median IMD was 38 microvessels/field at the hot spot (range, 18-80), and the median percentage of nuclei labeled by the PC-10 mAb was 50% (range, 0-95%). In the univariate analysis, regional lymph node negativity (P = 0.016), good performance status (PS) (PS >/= 90; P = 0.044), bcl-2 positivity (P = 0.070), and low vascularization (P = 0. 085) were significantly associated with a higher probability of complete remission. In the multivariate analysis (final model), only IMD (continuous variable; P = 0.045) and PS (P = 0.017) retained significance. As far as prognosis is concerned, in the univariate analysis, patients with tumors with low histological grading (grades 1-2; P = 0.006), p53 negative (P = 0.09), bcl-2 positive (P = 0.08), and high PCNA labeling (P = 0.06) had a significantly better disease-free survival. In the multivariate analysis, only grading (P = 0.003) and p53 (P = 0.04) retained significance for disease-free survival. For overall survival, in the univariate analysis, the following markers were significantly prognostic when only deaths due to progression are considered: response to therapy (P = 0.00001), PS (P = 0.04), nodal status (P = 0.028), PCNA (P = 0.04), p53 (P = 0. 08), and grading (P = 0.01). In the multivariate analysis, only patients who achieved complete response (P = 0.00002), high PCNA values (P = 0.002), and low histological grading (P = 0.01) retained a statistically significant probability of better overall survival. Our results suggest that in this series of H&N cancer patients the markers capable of predicting response to therapy are distinct from those associated with prognosis, once the remission has been achieved. This information is potentially useful to the clinician for developing a more rational therapeutic approach for H&N cancer patients eligible for concurrent chemoradiation therapy." @default.
• W1526072406 created "2016-06-24" @default.
• W1526072406 creator A5001588672 @default.
• W1526072406 creator A5001899541 @default.
• W1526072406 creator A5011668568 @default.
• W1526072406 creator A5030748289 @default.
• W1526072406 creator A5039504469 @default.
• W1526072406 creator A5063583733 @default.
• W1526072406 creator A5071308072 @default.
• W1526072406 creator A5073341946 @default.
• W1526072406 creator A5080135856 @default.
• W1526072406 date "1995-11-01" @default.
• W1526072406 modified "2023-09-23" @default.
• W1526072406 title "Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy." @default.
• W1526072406 cites W1487506158 @default.
• W1526072406 cites W1505534997 @default.
• W1526072406 cites W1524836561 @default.
• W1526072406 cites W1543443055 @default.
• W1526072406 cites W1592603695 @default.
• W1526072406 cites W175938947 @default.
• W1526072406 cites W1837651204 @default.
• W1526072406 cites W1878608668 @default.
• W1526072406 cites W1890740011 @default.
• W1526072406 cites W1967099784 @default.
• W1526072406 cites W1994025908 @default.
• W1526072406 cites W2018575860 @default.
• W1526072406 cites W2032950750 @default.
• W1526072406 cites W2038249986 @default.
• W1526072406 cites W2057943002 @default.
• W1526072406 cites W2070184707 @default.
• W1526072406 cites W2111465368 @default.
• W1526072406 cites W2137022580 @default.
• W1526072406 cites W2144322780 @default.
• W1526072406 cites W2151058265 @default.
• W1526072406 cites W2155882331 @default.
• W1526072406 cites W2167805334 @default.
• W1526072406 cites W2254112056 @default.
• W1526072406 cites W2319962899 @default.
• W1526072406 cites W2403160433 @default.
• W1526072406 cites W2416135976 @default.
• W1526072406 cites W2440720015 @default.
• W1526072406 cites W2468342816 @default.
• W1526072406 cites W3085323863 @default.
• W1526072406 cites W66673963 @default.
• W1526072406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9815934" @default.
• W1526072406 hasPublicationYear "1995" @default.
• W1526072406 type Work @default.
• W1526072406 sameAs 1526072406 @default.
• W1526072406 citedByCount "31" @default.
• W1526072406 countsByYear W15260724062014 @default.
• W1526072406 countsByYear W15260724062016 @default.
• W1526072406 crossrefType "journal-article" @default.
• W1526072406 hasAuthorship W1526072406A5001588672 @default.
• W1526072406 hasAuthorship W1526072406A5001899541 @default.
• W1526072406 hasAuthorship W1526072406A5011668568 @default.
• W1526072406 hasAuthorship W1526072406A5030748289 @default.
• W1526072406 hasAuthorship W1526072406A5039504469 @default.
• W1526072406 hasAuthorship W1526072406A5063583733 @default.
• W1526072406 hasAuthorship W1526072406A5071308072 @default.
• W1526072406 hasAuthorship W1526072406A5073341946 @default.
• W1526072406 hasAuthorship W1526072406A5080135856 @default.
• W1526072406 hasConcept C121608353 @default.
• W1526072406 hasConcept C126322002 @default.
• W1526072406 hasConcept C142724271 @default.
• W1526072406 hasConcept C143998085 @default.
• W1526072406 hasConcept C144301174 @default.
• W1526072406 hasConcept C146357865 @default.
• W1526072406 hasConcept C151730666 @default.
• W1526072406 hasConcept C190283241 @default.
• W1526072406 hasConcept C204232928 @default.
• W1526072406 hasConcept C2776530083 @default.
• W1526072406 hasConcept C2776694085 @default.
• W1526072406 hasConcept C2776833033 @default.
• W1526072406 hasConcept C2777546739 @default.
• W1526072406 hasConcept C2778239845 @default.
• W1526072406 hasConcept C2780849966 @default.
• W1526072406 hasConcept C2781451048 @default.
• W1526072406 hasConcept C34688535 @default.
• W1526072406 hasConcept C38180746 @default.
• W1526072406 hasConcept C502942594 @default.
• W1526072406 hasConcept C509974204 @default.
• W1526072406 hasConcept C55493867 @default.
• W1526072406 hasConcept C71924100 @default.
• W1526072406 hasConcept C86803240 @default.
• W1526072406 hasConceptScore W1526072406C121608353 @default.
• W1526072406 hasConceptScore W1526072406C126322002 @default.
• W1526072406 hasConceptScore W1526072406C142724271 @default.
• W1526072406 hasConceptScore W1526072406C143998085 @default.
• W1526072406 hasConceptScore W1526072406C144301174 @default.
• W1526072406 hasConceptScore W1526072406C146357865 @default.
• W1526072406 hasConceptScore W1526072406C151730666 @default.
• W1526072406 hasConceptScore W1526072406C190283241 @default.
• W1526072406 hasConceptScore W1526072406C204232928 @default.
• W1526072406 hasConceptScore W1526072406C2776530083 @default.
• W1526072406 hasConceptScore W1526072406C2776694085 @default.
• W1526072406 hasConceptScore W1526072406C2776833033 @default.
• W1526072406 hasConceptScore W1526072406C2777546739 @default.
• W1526072406 hasConceptScore W1526072406C2778239845 @default.

• next